Anxiety Disorders

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)